Acumen Pharmaceuticals Inc Total Liabilities
Acumen Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Acumen Pharmaceuticals Inc (ABOS) has total liabilities worth $46.15 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ABOS cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Acumen Pharmaceuticals Inc (2019–2025)
Total liabilities of Acumen Pharmaceuticals Inc from 2019 to 2025. This chart illustrates how Acumen Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Acumen Pharmaceuticals Inc (ABOS) long-term investment share to see how much of total assets are deployed in long-term investments.
Acumen Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Acumen Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
88 Energy Ltd
AU:88E
|
Australia | AU$362.67K |
|
Mnc Sky Vision Tbk
JK:MSKY
|
Indonesia | Rp537.10 Billion |
|
Korean Air Lines Co Ltd
KO:003495
|
Korea | ₩42.06 Trillion |
|
GiantStep Co. Ltd.
KQ:289220
|
Korea | ₩19.79 Billion |
|
BPM Minerals Ltd
AU:BPM
|
Australia | AU$518.02K |
|
Murano Global Investments PLC Ordinary Shares
NASDAQ:MRNO
|
USA | $15.88 Billion |
|
Dong Il Steel MFG Co Ltd
KO:002690
|
Korea | ₩19.03 Billion |
|
Gotland Rederi AB Series B
ST:GOTL-B
|
Sweden | Skr1.20 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Acumen Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ABOS total asset value.
Liquidity & Leverage Metrics
Acumen Pharmaceuticals Inc Total Liabilities Ratios Explained
Acumen Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Acumen Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Acumen Pharmaceuticals Inc (2019–2025)
The table below shows the annual total liabilities of Acumen Pharmaceuticals Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $52.40 Million | -8.35% |
| 2024-12-31 | $57.18 Million | +32.50% |
| 2023-12-31 | $43.15 Million | +452.38% |
| 2022-12-31 | $7.81 Million | +51.78% |
| 2021-12-31 | $5.15 Million | -91.83% |
| 2020-12-31 | $63.02 Million | +236.25% |
| 2019-12-31 | $18.74 Million | -- |
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement… Read more